DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-356

Gilead Sciences, Inc
Attn: Alan S. Taylor, PhD
Vice President, Regulatory Affairs
333 Lakeside Drive
Foster City CA 94404

Dear Dr. Taylor:

Please refer to your supplemental new drug application (SLR-001) dated September 6, 2002, received September 9, 2002 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act pursuant to 505(b)(1) for VIREAD® (tenofovir disoproxil fumarate) 300 mg Tablets.

We acknowledge receipt of your submissions dated September 19, 2002, and September 20, 2002, and received September 20, 2002, and September 23, 2002.

This supplemental new drug application (SLR-001) provides for the following revisions to the safety information in the VIREAD® professional package insert:

1. Changes "Renal insufficiency" to "Renal impairment" in the WARNINGS section and in the CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations sections;

2. Changes in the Drug Interaction Tables 1 and 2 and precautionary wording regarding the pharmacokinetic (PK) interaction between tenofovir disoproxil fumarate and didanosine (VIDEX and VIDEX-EC);

3. Changes in the WARNINGS section to strengthen the reporting of renal impairment with VIREAD® use and the monitoring of use in patients at risk for renal dysfunction;

4. Addition of a new section describing adverse events from spontaneous reports, entitled "ADVERSE REACTIONS, Observed During Clinical Practice."

5. Changes in the DOSAGE AND ADMINISTRATION section deleting the paragraph on concomitant administration of ddI and VIREAD®.

6. Replaces the date of the final professional package insert to the most current version.

This supplemental new drug application (SLR-001) also provides for the following revisions to the safety information in the VIREAD® patient package insert:

1. Changes in the "How should I take VIREAD®?" section deleting the directions for concomitant use of VIREAD® and ddI.

2. Addition of information on clinical studies, marketing experience, and kidney problems in the "What are the possible side effects of VIREAD®?" section.

3. Replaces the date for the patient package insert to the most current version.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert.)

Please submit the FPL electronically according to the guidance for industry titled *"Providing Regulatory Submissions in Electronic Format – NDA).* Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavyweight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-356/SLR-001." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Marsha S. Holloman, Regulatory Health Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure: Printed Labeling Submitted September 25, 2002 by the sponsor
(PI - page 1; PPI - page 22; Commercial Label - page 28; Free Goods Label - page 29)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Debra Birnkrant
12/2/02 09:31:13 AM
NDA 21-356